Clinical trial NCT02359968: PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer
Official title: PReoperative Chemoradiation With Paclitaxel-carboplatin or With Fluorouracil-oxaliplatine-acide Folinique (FOLFOX) for Resectable Esophageal and Junctional Cancer - A Randomized Phase II Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Esophageal Neoplasms
Gastro-esophageal Junction Cancer
Keywords: resectable esophageal
junctional cancer
FOLFOX
paclitaxel-carboplatin
Lead sponsor: Centre Oscar Lambret
Sponsor class: OTHER
Collaborators: name: National Cancer Institute, France
First posted: 2015-02-10
Enrollment: 106
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: Resectable esophageal or junctional cancer requires medical treatment by radiotherapy and chemotherapy followed by surgery. Currently, one of the most commonly used chemotherapy treatment is the FOLFOX. It is a combination of three drugs administered intravenously: fluorouracil, oxaliplatin and folinic acid. This is the standard treatment.

Another protocol of chemotherapy is widely used by certain European and American teams, due to promising results : a combination of two drugs administered intravenously: Paclitaxel and Carboplatin (CarboP-pacliT). At present, no clinical study has shown the superiority of one treatment over the other.

The objective of this Phase II study is to clarify clinical practice by comparing these two chemotherapy treatments.

Detailed description: There is no standard preoperative (neoadjuvant) chemoradiation (NCRT) regimen for resectable esophageal cancer, because most if all trials failed to show any survival advantage favoring pCRT when compared to surgery only. This failure had been related to the lack of power of some trials, as well as the ability of chemoradiation to potentiate post-operative morbidity (including mortality), and therefore hampering the accrual of its own survival benefit. Hopefully, meta-analyses showed that NCRT increases survival when compared to surgery only. However, in the clinical practice, this does not make easier the choice of the best NCRT treatment. It appeared that the radiation regimen that were used in each randomized trials were heterogeneous with respect with dose, fraction, length of treatment, fields, dosimetry planning, and quality control. This applies also to chemotherapy with respect with the kind of cytotoxics that were used (including number of drugs), as well as dosage, and the number of cycles, although most of the time cytotoxics were fluorouracil and cisplatin.

Dutch colleagues recently showed that NCRT with weekly carboplatin and paclitaxel increase survival, without increasing postoperative mortality. Of note, most tumors in this trial arose from the lower third of the esophagus and esogastric junction and these habitually correlate with less postoperative morbidity compared to upper third tumors. Moreover, the lung volume spared from radiation was greater in junctional tumors than in upper third cancers - a critical point in the development of radiation-induced pneumonitis and subsequent postoperative mortality. It is difficult to understand how this taxane-based chemotherapy is active, as it did not make better that fluorouracil-based regimen in non-operable patients, and as NCRT with taxanes makes radiation-induced pneumonitis more likely. The favorable impact of this NCRT may lie on its radiation regimen. A moderate total dose of radiation, smaller radial margins than in other trials and modern dosimetry with 3D-planning all improve the safety of treatment and of subsequent surgery. Finally, the favorable impact of the Dutch NCRT regimen may lies on the fact that it does not include cisplatin, a compound which has been found related to the occurrence of more sudden deaths than a non cisplatin-based regimen such as the FOLFOX combination (fluorouracil, oxaliplatin, folinic acid) in the setting of definitive chemoradiotherapy.

Our aim is to evaluate the short-term benefit (complete resection rate) and safety (severe postoperative rate) of 2 preoperative regimen, (carboplatin-paclitaxel or fluorouracil-oxaliplatin-folinic acid), combined to the Dutch radiation backbone, in operable esophageal and junctional (Siewert I-II) cancer. The present trial offers the unique opportunity to compare two therapeutic strategies that have already been shown to be efficient in large randomized controlled trials offering level-1 evidence.

Eligibility criteria: Inclusion Criteria:

* Resectable and operable esophageal cancer located under the carena (beyond 25 cm from the incisors) or junctional cancer (Siewert I or II)
* Invasive adenocarcinoma or squamous cell type (to stick to the population included in the CROSS trial)
* Patient who present with:

  * stage IIA (T3N0M0)
  * stage IIB (T1 N1 M0 or T2 N1 M0),
  * stage III (T3 N1 M0 or T4 N0 N1 M0) tumors
* ECOG performance status 0, 1 or 2
* Patient eligible for preoperative chemoradiation with either fluorouracil- oxaliplatin-folinic acid, or Paclitaxel-carboplatin
* Age ≥ 18
* Peripheral neuropathy ≤ NCI-CTC grade 1
* Adequate bone marrow reserve, normal renal and liver functions:

  * Neutrophil count ≥ 1500/mm3
  * Platelet count ≥ 100 000/mm3
  * Hemoglobin ≥ 10 g/dl (after transfusion, if necessary)
  * Creatinin \< 15mg/L
  * Clearance of creatinin (Cockcroft formulae) ≥ 60 ml/mn
  * Prothrombin time ≥ 60%
  * ASAT-ALAT ≤2.5 x ULN
  * Total bilirubin \< 1.5 x ULN
  * Albumin greater the lower limit of normal
* Start of treatment within 28 days after randomization
* Negative pregnancy test (serum beta-HCG) performed within 1 week prior to start of study treatment in females with reproductive potential
* Patient covered by government health insurance
* Patient who provide a signed written informed consent form

Exclusion Criteria:

* Patient who present with stage I or stage IIA (including T2 N0 M0) or stage IV
* Patient who present with common contraindications for surgery related to patient status
* Patient who present with common contraindications for surgery related to disease extension
* Patient who present with common contraindication to radiochemotherapy with either fluorouracile-cisplatin or with paclitaxel-carboplatin

Primary outcomes:
measure: Short-term benefit of 2 preoperative regimen: complete resection rate AND severe (grade ≥ 3) postoperative morbidity/mortality according to the Clavien-Dindo classification
timeFrame: up to 30 days after surgery
Secondary outcomes:
measure: Rate of completion of full treatment without modification
timeFrame: up to 58 days
measure: Evaluation of the efficacy of both regimen in term of overall survival
timeFrame: From date of inclusion until the date of death from any cause assessed up to 36 months after the last surgery
measure: Evaluation of the efficacy of both regimen in term of disease-free survival
timeFrame: From date of inclusion until the date of first documented progression whichever came first, assessed up to 36 months after the last surgery
measure: Evaluation of the safety of the evaluated regimens in terms of preoperative mortality.
timeFrame: From registration to surgery
measure: Evaluation of the safety of the evaluated regimens in terms of preoperative morbidities, postoperative morbidities, respiratory morbidities.
timeFrame: From start of treatment to end of study
measure: Evaluation of the efficacy of both regimen in term of Pathological response rate
timeFrame: Surgery
measure: Evaluation of the efficacy of both regimen in term of quality of life
timeFrame: Up to 3 years after surgery
Other outcomes:
measure: DVH (CoDose-Volume-Histogram (DVH) and postoperative respiratory morbidity
timeFrame: up to 30 days after the beginning of radiotherapy
measure: Comparison of both arms in terms of safety and efficacy
timeFrame: From date of inclusion until the date of death from any cause assessed up to 36 months after the last surgery
measure: Net treatment benefit estimation
timeFrame: From date of inclusion until the date of death from any cause assessed up to 36 months after the last surgery
measure: Prognostic factor and treatment effect controlling for possible confounding factors
timeFrame: From date of inclusion until the date of first documented progression whichever came first, assessed up to 36 months after the last surgery
Locations:
city: Angers
country: France
facility: ICO Paul Papin
city: Bordeaux
country: France
facility: CHU Bordeaux
city: Lille
country: France
facility: University Hospital of Lille
city: Lille
country: France
facility: Centre Oscar Lambret
city: Marseille
country: France
facility: Hôpital La Timone
city: Marseille
country: France
facility: Hôpital Nord
city: Montpellier
country: France
facility: ICM - Val d'Aurelle
city: Pierre-Bénite
country: France
facility: CH Lyon sud
city: Rennes
country: France
facility: Centre Eugène Marquis
city: Saint-Herblain
country: France
facility: ICO René Gauducheau
Study officials:
affiliation: Centre Oscar Lambret
name: Antoine ADENIS, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital of Lille
name: Guillaume PIESSEN, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Messager M, Mirabel X, Tresch E, Paumier A, Vendrely V, Dahan L, Glehen O, Vasseur F, Lacornerie T, Piessen G, El Hajbi F, Robb WB, Clisant S, Kramar A, Mariette C, Adenis A. Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial. BMC Cancer. 2016 May 18;16:318. doi: 10.1186/s12885-016-2335-9.